(LOWER GWYNEDD, Pennsylvania, March 15, 2023) Tavotek Biotherapeutics, a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs, was named a finalist for the 2022 Emerging Company of the Year Award by Life Sciences Pennsylvania.

The Emerging Company of the Year Award recognizes a company or organization that has experienced significant growth and/or achievement in 2022, while contributing positively to its community and the overall life sciences business climate of the Commonwealth.

Dr. Mark Chiu, Chief Scientific Officer said, “We are thrilled to be named a finalist for the Emerging Company of the Year Award. This recognition is a testament to our hard work and dedication to advancing life sciences and positively contributing to our community.” 

About Tavotek

Tavotek Biotherapeutics is a multi-specific antibody drug company with the world's cutting-edge protein engineering technology, focusing on oncology and immunology diseases. The company's R&D is mainly built on three innovative breakthrough technology platforms, namely: TavoSelectTM, a bacteriophage biobank with AI assisted 3D selection; TavoPreciseTM, a sophisticated protein engineering platform that supports the development of bispecific and multi-specific antibodies, and TavoELITETM, an innovative synthetic biologic platform focusing on overcoming intracellular undruggable targets with particular focus on protein-protein interaction. With unique innovative R&D capabilities, biomarker-driven clinical development strategies, and efficient execution efficiency, Tavotek will provide treatment options with better efficacy, safety and convenience to advance medical care for patients.